Medisafe 1 Technologies Signs Marketing and Distribution Agreement with Health Product Carrier

Mar 12, 2012, 06:00 ET from Medisafe 1 Technologies Corp.

JERUSALEM, March 12, 2012 /PRNewswire/ --

Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has signed a distribution agreement with Natural Dream Laboratories Company Ltd ( for Medisafe 1 to carry a wide range of health related products in the Natural Dream laboratories Company product line.

Natural Dream Laboratories Company distributes a robust commercial product line including treatments for several health related disorders mainly relating to skin diseases.  

"The signing of this distribution agreement enables Medisafe 1 Technologies to offer a wider range of medical products to our potential consumers," said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. "Adding products that have proven themselves to be commercially-viable increases the ability of Medisafe 1 Technologies to generate revenues, with the intent of providing value to our company and benefits to our shareholders."

About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle.  Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated.  Medisafe 1 Technologies Corp. public filings may be viewed at

Jacob Elhadad

SOURCE Medisafe 1 Technologies Corp.